AGÕæÈ˹ٷ½

STOCK TITAN

Neogen Corp SEC Filings

NEOG NASDAQ

Welcome to our dedicated page for Neogen SEC filings (Ticker: NEOG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Food safety diagnostics might feel far from Wall Street, yet Neogen’s supply-chain complexity shows up in hundreds of pages of disclosures. Tracking which genomic test kit drives revenue, or when management sells shares, is difficult. That’s why investors hunting for “Neogen insider trading Form 4 transactions� or the latest “Neogen quarterly earnings report 10-Q filing� often lose hours scrolling through EDGAR.

Stock Titan fixes this. Our AI reads every 10-K, 10-Q, 8-K and proxy the moment it is released, pushes “Neogen Form 4 insider transactions real-time� to your dashboard, and offers “Neogen SEC filings explained simply� with crisp language and data visualizations. Within seconds you’ll see a “Neogen earnings report filing analysis,� flagging segment sales for food safety, animal safety and genomics, plus cash flow shifts tied to acquisitions. Interactive links jump you straight to risk factors, while sidebars answer “understanding Neogen SEC documents with AI� without legalese.

Want specifics? The “Neogen annual report 10-K simplified� highlights R&D spend on LAMP molecular assays and global compliance costs. The “Neogen proxy statement executive compensation� module benchmarks pay packages against peer diagnostics firms. Alerts on “Neogen executive stock transactions Form 4� reveal buying patterns before material announcements, and our dashboard keeps the “Neogen 8-K material events explained� in plain sight when recalls or mergers hit. Whether you compare quarter-over-quarter allergen test kit sales, monitor insider sentiment, or review governance votes, Stock Titan delivers the intelligence you need, updated in real time and ready for decision making.

Filing
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

Neogen Corp (NEOG) officer John Edward Adent reported the vesting and settlement of restricted stock units into common stock on August 18, 2025. The filing shows 35,736 RSUs vested and were settled for 35,736 shares at an effective price of $5.43 per share, increasing his direct holdings to 307,012 shares following the transaction. The Form 4 was signed by an attorney-in-fact on August 20, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Neogen Corp (NEOG) insider activity: Douglas Edward Jones, the Chief Operating Officer and a director, reported transactions on 08/18/2025 where 14,294 restricted stock units vested and were settled into 14,294 shares at an implied price of $5.43 per share, increasing his beneficial ownership to 86,007 shares. The filing also shows a separate disposition of 4,160 shares at $5.43, leaving 81,847 shares after that sale. The Form 4 was signed by an attorney-in-fact on 08/20/2025. The filer notes each RSU is the economic equivalent of one common share and that the RSUs vested and were settled on 08/18/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Neogen Corp (NEOG) Form 4 summary: Chief Financial Officer David H. Naemura reported vesting and settlement of 14,294 restricted stock units on 08/18/2025 at an indicated price of $5.43 per share, resulting in acquisition of 14,294 shares. The filing also shows a contemporaneous disposition of 5,947 shares at $5.43, leaving the reporting person with 69,781 shares after the transactions. The form was signed by an attorney-in-fact on 08/20/2025. This filing documents an insider equity vesting event and partial sale of shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Neogen Corp (NEOG) insider activity: Amy M. Rocklin, Chief Legal Officer, had 10,324 restricted stock units vest on 08/18/2025 and those RSUs were settled into 10,324 shares at $5.43 per share. On the same date she acquired 10,324 shares and sold 3,005 shares at $5.43, leaving her with 44,170 shares beneficially owned following the transactions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Neogen Corp (NEOG) insider transaction: John Patrick Moylan, Chief Accounting Officer and director, reported that on 08/18/2025 1,985 restricted stock units vested and were settled for 1,985 shares of common stock at a per-share value of $5.43. To cover obligations, 593 shares were disposed of at the same price, leaving Mr. Moylan with 14,347 shares beneficially owned after the transactions. The Form 4 was filed on 08/20/2025 and signed by an attorney-in-fact.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

David H. Naemura, identified as an officer (CFO) and director, reported insider purchases for NEOG on 08/15/2025. He acquired 230,203 shares of Neogen common stock at $5.43 per share, bringing his total beneficial ownership to 291,637 shares. The filing also reports derivative securities: 591,690 rights/options to buy common stock with a $5.43 exercise price, acquired 08/15/2025 and exercisable immediately, expiring 08/15/2035. The disclosure states the options vest in equal annual installments over the first three anniversaries and that performance stock units vest in full at the three-year anniversary. The form was signed by an attorney-in-fact on 08/19/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Amy M. Rocklin, Chief Legal Officer of Neogen Corp (NEOG), reported equity awards and option grants that increase her direct ownership. She acquired 119,705 common shares at $5.43 per share, bringing her direct beneficial ownership to 156,556 shares. In addition, she received a derivative award giving the right to buy 307,680 shares at an exercise price of $5.43, exercisable through 08/15/2035.

The filing notes the option grants vest in equal annual installments over the first three anniversaries of the grant and that performance stock units vest in full at the three-year anniversary. All reported holdings are direct ownership.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Neogen Corp insider filing: John Patrick Moylan, identified as a director and Chief Accounting Officer, reported purchases on 08/15/2025. He acquired 18,416 shares of NEOG common stock at a price of $5.43 per share, bringing his total reported beneficial ownership to 31,371 shares. The filing also reports acquisition of derivative rights described as the right to buy 47,336 shares at a $5.43 exercise price, exercisable beginning 08/15/2025 and expiring 08/15/2035, with 47,336 underlying shares shown as beneficially owned following the transaction. The filing notes that options and restricted stock units vest in equal annual installments on each of the first three anniversary dates of the grants.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Nassif Mikheal, identified as CEO and a director of Neogen Corp (NEOG), reported multiple acquisitions on 08/15/2025. He acquired 184,162 shares of common stock and 414,365 shares of common stock at $5.43 per share, leaving 598,527 shares beneficially owned after the transactions. He also acquired derivative rights (options/RSU/PSU grants) exercisable into 1,065,042 and 473,352 shares with an exercise/conversion price of $5.43 and expiration/vesting noted as 08/15/2035. The filing includes vesting schedule notes: some options/RSUs vest over three years, others over four years, and PSUs vest in total at the three-year anniversary. The Form 4 was signed by an attorney-in-fact on 08/19/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider

FAQ

What is the current stock price of Neogen (NEOG)?

The current stock price of Neogen (NEOG) is $5.75 as of September 1, 2025.

What is the market cap of Neogen (NEOG)?

The market cap of Neogen (NEOG) is approximately 1.2B.
Neogen Corp

NASDAQ:NEOG

NEOG Rankings

NEOG Stock Data

1.25B
214.72M
0.85%
112.75%
7.94%
Diagnostics & Research
In Vitro & in Vivo Diagnostic Substances
United States
LANSING